Methods of administering Belumosudil for treatment of chronic graft versus host disease
US12097202B2 · kind B2 · utility
0Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2023 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Feb 3, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.